|
Participant factors
|
|
Age of subjects
|
Y
|
Y
|
Y
|
Y
|
|
Gender of subjects
|
Y
|
Y
|
Y
|
Y
|
|
Handedness of subjects
|
Y
|
Y
|
Y
|
Y
|
|
Subjects prescribed medication
|
N
|
N
|
Y
|
N
|
|
Use of CNS active drugs (e.g. anti-convulsants)
|
N
|
N
|
Y
|
Y
|
|
Presence of neurological/psychiatric disorders
|
N
|
N
|
Y
|
Y
|
|
Any medical conditions
|
N
|
N
|
Y
|
Y
|
|
History of specific repetitive motor activity
|
N
|
N
|
Y
|
N
|
|
Methodological factors
|
|
Position and contact of EMG electrodes
|
Y
|
Y
|
Y
|
Y
|
|
Amount of contraction of target muscles
|
Y
|
Y
|
Y
|
Y
|
|
Prior motor activity of the muscle to be tested
|
Y
|
Y
|
Y
|
Y
|
|
Relaxation of muscles other than those tested
|
N
|
N
|
N
|
N
|
|
Coil type (size and geometry)
|
Y
|
Y
|
Y
|
Y
|
|
Coil orientation
|
Y
|
Y
|
Y
|
Y
|
|
Direction of induced current in the brain
|
Y
|
N
|
N
|
Y
|
|
Coil location and stability
|
Y
|
Y
|
Y
|
Y
|
|
Type of stimulator used (e.g. brand)
|
Y
|
Y
|
Y
|
Y
|
|
Stimulation intensity
|
Y
|
Y
|
Y
|
Y
|
|
Pulse shape (monophasic or biphasic)
|
N
|
N
|
N
|
Y
|
|
Determination of optimal hotspot
|
Y
|
Y
|
Y
|
Y
|
|
The time between MEP trials
|
N
|
N
|
N
|
Y
|
|
Time between days of testing
|
Y
|
Y
|
Y
|
Y
|
|
Subject attention (level of arousal) during testing
|
N
|
N
|
N
|
Y
|
|
Method for determining threshold (active/resting)
|
Y
|
Y
|
Y
|
Y
|
|
Number of MEP measures made
|
Y
|
Y
|
Y
|
Y
|
|
Method for determining MEP size during analysis
|
Y
|
Y
|
Y
|
Y
|
|
Total score/26
|
17
|
16
|
21
|
23
|
